Holm Malin, Pettersen Frank Olav, Kvale Dag
Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway.
Curr HIV Res. 2008 Jan;6(1):49-58. doi: 10.2174/157016208783571955.
The immunopathogenic factor programmed cell death 1 (PD-1) was compared to CD38 and HIV RNA in predicting actual CD4+ T cell loss rate indicative for clinical progression. This cross sectional exploratory study included 50 consecutive, healthy HIV-infected patients off antiretroviral therapy (ART); 43 had the required observation times > 12 months. PD-1 and CD38 were determined on various T cell subsets by FACS analyses in fresh and later in parallel cryopreserved samples. Here more rapid progressors were relatively defined by having CD4 loss rates < median at -45.7/microl/year. PD-1 and CD38 densities in fresh blood were lower (p<0.001) in patients on ART (n=14) and seronegative controls (n=8). CD4 loss rates correlated significantly to current HIV RNA (R=-0.30), CD38 (R=-0.33) and PD-1 densities (R=-0.38) on CD8+ T cells, and best to DeltaCD38, i.e. the difference in CD38 between the PD-1+CD8+ and CD8+ subsets (R=-0.51). PD-1 was highest on the CD27+CD28-CD8+ subset with best correlation to progression (R=-0.54) in rapid progressors. Logistic regression models from HIV RNA, CD38 and PD-1 predicting rapid progression included PD-1 as best independent variable in combination with DeltaCD38 or CD38, supported by similar results from multiple regression analyses. PD-1 did not correlate with any of the other candidate variables. Cryopreservation reduced the CD38+ and PD-1+ fractions but corresponding densities became more suppressed through a non-linear loss most pronounced in CD38hi/PD-1hi cells with loss of predictive power. In conclusion, PD-1 was the best independent predictor for CD4 loss rates in fresh blood compared with CD38 and HIV RNA.
将免疫致病因子程序性细胞死亡1(PD-1)与CD38和HIV RNA进行比较,以预测指示临床进展的实际CD4+T细胞丢失率。这项横断面探索性研究纳入了50例连续的、接受抗逆转录病毒治疗(ART)的健康HIV感染患者;其中43例有>12个月的所需观察时间。通过流式细胞术分析在新鲜样本以及随后平行冻存的样本中测定各种T细胞亚群上的PD-1和CD38。在这里,进展较快者相对定义为CD4丢失率<-45.7/微升/年的中位数。接受ART治疗的患者(n=14)和血清学阴性对照者(n=8)新鲜血液中的PD-1和CD38密度较低(p<0.001)。CD4丢失率与CD8+T细胞上当前的HIV RNA(R=-0.30)、CD38(R=-0.33)和PD-1密度(R=-0.38)显著相关,与DeltaCD38(即PD-1+CD8+和CD8+亚群之间CD38的差异)相关性最佳(R=-0.51)。在进展较快者中,PD-1在CD27+CD28-CD8+亚群上最高,与进展的相关性最佳(R=-0.54)。由HIV RNA、CD38和PD-1预测快速进展的逻辑回归模型将PD-1作为最佳独立变量,与DeltaCD38或CD38联合使用,多元回归分析的类似结果支持了这一点。PD-1与任何其他候选变量均无相关性。冻存降低了CD38+和PD-1+比例,但相应密度通过非线性损失变得更受抑制,在CD38高/PD-1高细胞中最为明显,且失去了预测能力。总之,与CD38和HIV RNA相比,PD-1是新鲜血液中CD4丢失率的最佳独立预测指标。